Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.79 -0.30 (-1.03%)
Official Closing Price Updated: 4:10 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,376,098
Open 29.09
Bid (Size) 28.85 (1)
Ask (Size) 28.86 (19)
Prev. Close 29.09
Today's Range 28.71 - 29.40
52wk Range 28.30 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 5.70%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-43.84%
-43.84%
1 Month
-7.67%
-7.67%
3 Month
-18.63%
-18.63%
6 Month
-24.97%
-24.97%
1 Year
-43.25%
-43.25%

More News

Read More
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate
Via Benzinga
Diamonds in the Rough: 3 Undervalued Stocks with Huge Upside
Via InvestorPlace
This Is What Whales Are Betting On Pfizer
Via Benzinga
Is Pfizer Stock a Buy Now?
Via The Motley Fool
Why Pfizer Stock Is Sinking Today
Via The Motley Fool
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
Via Benzinga
3 Stocks at the Forefront of Personalized Medicine Trend
Via InvestorPlace
7 Compelling Stocks to Buy That are Sitting at 52-Week Lows
Via InvestorPlace
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
Pfizer Tumbles After Abandoning Weight-Loss Pill
Via Talk Markets
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Is Hub Cyber Security (HUBC) Stock Up 30% Today?
Via InvestorPlace
Why Is Altimmune (ALT) Stock Up 43% Today?
Via InvestorPlace
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.